These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 17614878)

  • 41. Interleukin-32α production is regulated by MyD88-dependent and independent pathways in IL-1β-stimulated human alveolar epithelial cells.
    Ko NY; Mun SH; Lee SH; Kim JW; Kim DK; Kim HS; Her E; Kim SH; Won HS; Shin HS; Kim HS; Kim YM; Choi WS
    Immunobiology; 2011; 216(1-2):32-40. PubMed ID: 20430472
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Targeting phosphoinositide 3-kinase: moving towards therapy.
    Marone R; Cmiljanovic V; Giese B; Wymann MP
    Biochim Biophys Acta; 2008 Jan; 1784(1):159-85. PubMed ID: 17997386
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Phosphoinositide-3 kinase inhibition modulates responses to rhinovirus by mechanisms that are predominantly independent of autophagy.
    Ismail S; Stokes CA; Prestwich EC; Roberts RL; Juss JK; Sabroe I; Parker LC
    PLoS One; 2014; 9(12):e116055. PubMed ID: 25541728
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Critical role for lipid raft-associated Src kinases in activation of PI3K-Akt signalling.
    Arcaro A; Aubert M; Espinosa del Hierro ME; Khanzada UK; Angelidou S; Tetley TD; Bittermann AG; Frame MC; Seckl MJ
    Cell Signal; 2007 May; 19(5):1081-92. PubMed ID: 17275257
    [TBL] [Abstract][Full Text] [Related]  

  • 45. HIF-1α inhibition ameliorates an allergic airway disease via VEGF suppression in bronchial epithelium.
    Kim SR; Lee KS; Park HS; Park SJ; Min KH; Moon H; Puri KD; Lee YC
    Eur J Immunol; 2010 Oct; 40(10):2858-69. PubMed ID: 20827786
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The role of macrophages in obstructive airways disease: chronic obstructive pulmonary disease and asthma.
    Pappas K; Papaioannou AI; Kostikas K; Tzanakis N
    Cytokine; 2013 Dec; 64(3):613-25. PubMed ID: 24084332
    [TBL] [Abstract][Full Text] [Related]  

  • 47. PI3K isoform-selective inhibitors: next-generation targeted cancer therapies.
    Wang X; Ding J; Meng LH
    Acta Pharmacol Sin; 2015 Oct; 36(10):1170-6. PubMed ID: 26364801
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Class IA phosphoinositide 3-kinase isoforms and human tumorigenesis: implications for cancer drug discovery and development.
    Wee S; Lengauer C; Wiederschain D
    Curr Opin Oncol; 2008 Jan; 20(1):77-82. PubMed ID: 18043260
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Targeting the phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway: an emerging treatment strategy for squamous cell lung carcinoma.
    Beck JT; Ismail A; Tolomeo C
    Cancer Treat Rev; 2014 Sep; 40(8):980-9. PubMed ID: 25037117
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Inhibition of VEGF blocks TGF-beta1 production through a PI3K/Akt signalling pathway.
    Lee KS; Park SJ; Kim SR; Min KH; Lee KY; Choe YH; Hong SH; Lee YR; Kim JS; Hong SJ; Lee YC
    Eur Respir J; 2008 Mar; 31(3):523-31. PubMed ID: 18057050
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Targeting phosphoinositide-3-kinase-delta with theophylline reverses corticosteroid insensitivity in chronic obstructive pulmonary disease.
    To Y; Ito K; Kizawa Y; Failla M; Ito M; Kusama T; Elliott WM; Hogg JC; Adcock IM; Barnes PJ
    Am J Respir Crit Care Med; 2010 Oct; 182(7):897-904. PubMed ID: 20224070
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Phosphoinositide 3-kinase assay in breast cancer cell extracts.
    Bilancio A; Migliaccio A
    Methods Mol Biol; 2014; 1204():145-53. PubMed ID: 25182768
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Both p110alpha and p110beta isoforms of phosphatidylinositol 3-OH-kinase are required for insulin signalling in the hypothalamus.
    Tups A; Anderson GM; Rizwan M; Augustine RA; Chaussade C; Shepherd PR; Grattan DR
    J Neuroendocrinol; 2010 Jun; 22(6):534-42. PubMed ID: 20236230
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Frontline: The p85alpha isoform of phosphoinositide 3-kinase is essential for a subset of B cell receptor-initiated signaling responses.
    Hess KL; Donahue AC; Ng KL; Moore TI; Oak J; Fruman DA
    Eur J Immunol; 2004 Nov; 34(11):2968-76. PubMed ID: 15384044
    [TBL] [Abstract][Full Text] [Related]  

  • 55. PI 3-kinase inhibition: a therapeutic target for respiratory disease.
    Finan PM; Thomas MJ
    Biochem Soc Trans; 2004 Apr; 32(Pt 2):378-82. PubMed ID: 15046612
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Development and application of PI3K assays for novel drug discovery.
    Yanamandra M; Mitra S; Giri A
    Expert Opin Drug Discov; 2015 Feb; 10(2):171-86. PubMed ID: 25547459
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Selective PI3Kδ inhibitors, a review of the patent literature.
    Norman P
    Expert Opin Ther Pat; 2011 Nov; 21(11):1773-90. PubMed ID: 22017414
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Potential of helper-dependent adenoviral vectors in modulating airway innate immunity.
    Kushwah R; Cao H; Hu J
    Cell Mol Immunol; 2007 Apr; 4(2):81-9. PubMed ID: 17484801
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Targeting PI3K isoforms and SHIP in the immune system: new therapeutics for inflammation and leukemia.
    Blunt MD; Ward SG
    Curr Opin Pharmacol; 2012 Aug; 12(4):444-51. PubMed ID: 22483603
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Targeting the phosphatidylinositol 3-kinase pathway in airway smooth muscle: rationale and promise.
    Krymskaya VP
    BioDrugs; 2007; 21(2):85-95. PubMed ID: 17402792
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.